Analysed KYMERA THERAPEUTICS INC (KYMR:NASDAQ) News Sources
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma
13-04-2026
yahoo.com
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
09-04-2026
yahoo.com
Does Positive KT-621 Atopic Dermatitis Data Change The Bull Case For Kymera Therapeutics (KYMR)?
30-03-2026
yahoo.com
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
28-03-2026
yahoo.com
What is the current price of KYMERA THERAPEUTICS INC (KYMR:NASDAQ)?
The current price of KYMERA THERAPEUTICS INC (KYMR:NASDAQ) is $88.23.
KYMERA THERAPEUTICS INC (KYMR:NASDAQ) absolute price change since previous trading day?
The absolute price change of KYMERA THERAPEUTICS INC (KYMR:NASDAQ) since the previous trading day is $2.09.
KYMERA THERAPEUTICS INC (KYMR:NASDAQ) percentage price change since previous trading day?
The percentage price change of KYMERA THERAPEUTICS INC (KYMR:NASDAQ) since the previous trading day is 2.4263%.
What is the most recent average sentiment score for KYMERA THERAPEUTICS INC (KYMR:NASDAQ)?
The most recent average sentiment score for KYMERA THERAPEUTICS INC (KYMR:NASDAQ) is 89 out of 100.
What is the most recent average sentiment for KYMERA THERAPEUTICS INC (KYMR:NASDAQ)?
The most recent sentiment for KYMERA THERAPEUTICS INC (KYMR:NASDAQ) is .
SEC-8K** Filing Available For KYMERA THERAPEUTICS INC (KYMR:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.